Published in AIDS Weekly, October 6th, 1997
Under the agreement, Genome Therapeutics employs its bioinformatics, high-throughput sequencing and functional genomics capabilities to identify and validate genes and associated proteins as drug discovery targets that can be used by Schering-Plough to develop antifungal treatments. Schering-Plough receives exclusive access to the genomic information developed in the collaboration related to two medically important fungal pathogens, Candida...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.